Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 26;34(13):1667-78.
doi: 10.1038/onc.2014.105. Epub 2014 Apr 28.

TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition

Affiliations

TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition

G-H Ha et al. Oncogene. .

Abstract

Deregulation of the transforming acidic coiled-coil protein 3 (TACC3), an important factor in the centrosome-microtubule system, has been linked to a variety of human cancer types. We have recently reported on the oncogenic potential of TACC3; however, the molecular mechanisms by which TACC3 mediates oncogenic function remain to be elucidated. In this study, we show that high levels of TACC3 lead to the accumulation of DNA double-strand breaks (DSBs) and disrupt the normal cellular response to DNA damage, at least in part, by negatively regulating the expression of ataxia telangiectasia mutated (ATM) and the subsequent DNA damage response (DDR) signaling cascade. Cells expressing high levels of TACC3 display defective checkpoints and DSB-mediated homologous recombination (HR) and non-homologous end joining (NHEJ) repair systems, leading to genomic instability. Importantly, high levels of TACC3 confer cellular sensitization to radiation and poly(ADP-ribose) polymerase (PARP) inhibition. Overall, our findings provide critical information regarding the mechanisms by which TACC3 contributes to genomic instability, potentially leading to cancer development, and suggest a novel prognostic, diagnostic and therapeutic strategy for the treatment of cancer types expressing high levels of TACC3.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Science. 2012 Sep 7;337(6099):1231-5 - PubMed
    1. EMBO Rep. 2003 Sep;4(9):844-9 - PubMed
    1. Cell Res. 2008 Jan;18(1):134-47 - PubMed
    1. BMC Genomics. 2010 Oct 18;11:576 - PubMed
    1. Biochem J. 2002 Apr 1;363(Pt 1):195-200 - PubMed

Publication types

MeSH terms

Substances